BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

336 related articles for article (PubMed ID: 19549707)

  • 1. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie.
    Lorenzen S; Schuster T; Porschen R; Al-Batran SE; Hofheinz R; Thuss-Patience P; Moehler M; Grabowski P; Arnold D; Greten T; Müller L; Röthling N; Peschel C; Langer R; Lordick F
    Ann Oncol; 2009 Oct; 20(10):1667-73. PubMed ID: 19549707
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platinum-based chemotherapy plus cetuximab in head and neck cancer.
    Vermorken JB; Mesia R; Rivera F; Remenar E; Kawecki A; Rottey S; Erfan J; Zabolotnyy D; Kienzer HR; Cupissol D; Peyrade F; Benasso M; Vynnychenko I; De Raucourt D; Bokemeyer C; Schueler A; Amellal N; Hitt R
    N Engl J Med; 2008 Sep; 359(11):1116-27. PubMed ID: 18784101
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase II trial of paclitaxel, fluorouracil, and cisplatin in patients with advanced carcinoma of the esophagus.
    Ilson DH; Ajani J; Bhalla K; Forastiere A; Huang Y; Patel P; Martin L; Donegan J; Pazdur R; Reed C; Kelsen DP
    J Clin Oncol; 1998 May; 16(5):1826-34. PubMed ID: 9586897
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase II study of pemetrexed in combination with cisplatin and cetuximab in recurrent or metastatic squamous cell carcinoma of the head and neck.
    Vermorken JB; Licitra L; Stöhlmacher-Williams J; Dietz A; Lopez-Picazo JM; Hamid O; Hossain AM; Chang SC; Gauler TC
    Eur J Cancer; 2013 Sep; 49(13):2877-83. PubMed ID: 23726971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neoadjuvant Chemotherapy with Divided-dose Docetaxel, Cisplatin and Fluorouracil for Patients with Squamous Cell Carcinoma of the Esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Kato T; Kitadani J; Tabata H; Takeuchi A; Iwahashi M; Yamaue H
    Anticancer Res; 2016 Feb; 36(2):829-34. PubMed ID: 26851048
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase III study comparing cisplatin plus fluorouracil to paclitaxel, cisplatin, and fluorouracil induction chemotherapy followed by chemoradiotherapy in locally advanced head and neck cancer.
    Hitt R; López-Pousa A; Martínez-Trufero J; Escrig V; Carles J; Rizo A; Isla D; Vega ME; Martí JL; Lobo F; Pastor P; Valentí V; Belón J; Sánchez MA; Chaib C; Pallarés C; Antón A; Cervantes A; Paz-Ares L; Cortés-Funes H
    J Clin Oncol; 2005 Dec; 23(34):8636-45. PubMed ID: 16275937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of docetaxel and cisplatin chemotherapy in 5-fluorouracil/cisplatin pretreated esophageal cancer.
    Shim HJ; Cho SH; Hwang JE; Bae WK; Song SY; Cho SB; Lee WS; Joo YE; Na KJ; Chung IJ
    Am J Clin Oncol; 2010 Dec; 33(6):624-8. PubMed ID: 20142726
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Platinum-based chemotherapy plus cetuximab for the first-line treatment of Japanese patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck: results of a phase II trial.
    Yoshino T; Hasegawa Y; Takahashi S; Monden N; Homma A; Okami K; Onozawa Y; Fujii M; Taguchi T; de Blas B; Beier F; Tahara M
    Jpn J Clin Oncol; 2013 May; 43(5):524-31. PubMed ID: 23479384
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part).
    Vermorken JB; Peyrade F; Krauss J; Mesía R; Remenar E; Gauler TC; Keilholz U; Delord JP; Schafhausen P; Erfán J; Brümmendorf TH; Iglesias L; Bethe U; Hicking C; Clement PM
    Ann Oncol; 2014 Mar; 25(3):682-688. PubMed ID: 24567516
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction chemotherapy with docetaxel, cisplatin and 5-fluorouracil followed by radiotherapy with cetuximab for locally advanced squamous cell carcinoma of the head and neck.
    Keil F; Selzer E; Berghold A; Reinisch S; Kapp KS; De Vries A; Greil R; Bachtiary B; Tinchon C; Anderhuber W; Burian M; Kasparek AK; Elsäßer W; Kainz H; Riedl R; Kopp M; Kornek G
    Eur J Cancer; 2013 Jan; 49(2):352-9. PubMed ID: 22981499
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Clinical evaluation of DLF, CLF and DFM regimens based on platinum compound plus 5-fluorouracil for treatment of advanced esophageal carcinoma].
    Jiang Y; Qiu XH; Yang YX; Zhang SQ; Chen ZM
    Ai Zheng; 2006 Aug; 25(8):1029-34. PubMed ID: 16965688
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase 2 Open Label, Single-Arm Trial to Evaluate the Combination of Cetuximab Plus Taxotere, Cisplatin, and 5-Flurouracil as an Induction Regimen in Patients With Unresectable Squamous Cell Carcinoma of the Head and Neck.
    Mesía R; Vázquez S; Grau JJ; García-Sáenz JA; Lozano A; García C; Carles J; Irigoyen A; Mañós M; García-Paredes B; del Barco E; Taberna M; Escobar Y; Cruz JJ;
    Int J Radiat Oncol Biol Phys; 2016 Feb; 94(2):289-96. PubMed ID: 26675064
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I/II trial of 2-weekly docetaxel combined with cisplatin plus fluorouracil in metastatic esophageal cancer (JCOG0807).
    Hironaka S; Tsubosa Y; Mizusawa J; Kii T; Kato K; Tsushima T; Chin K; Tomori A; Okuno T; Taniki T; Ura T; Matsushita H; Kojima T; Doki Y; Kusaba H; Fujitani K; Taira K; Seki S; Nakamura T; Kitagawa Y;
    Cancer Sci; 2014 Sep; 105(9):1189-95. PubMed ID: 25041052
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study).
    Pinto C; Di Fabio F; Siena S; Cascinu S; Rojas Llimpe FL; Ceccarelli C; Mutri V; Giannetta L; Giaquinta S; Funaioli C; Berardi R; Longobardi C; Piana E; Martoni AA
    Ann Oncol; 2007 Mar; 18(3):510-7. PubMed ID: 17164226
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study.
    Burtness B; Goldwasser MA; Flood W; Mattar B; Forastiere AA;
    J Clin Oncol; 2005 Dec; 23(34):8646-54. PubMed ID: 16314626
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I Study of Docetaxel Plus Nedaplatin in Patients With Metastatic or Recurrent Esophageal Squamous Cell Carcinoma After Cisplatin Plus 5-Fluorouracil Treatment.
    Kajiura S; Hosokawa A; Yoshita H; Ueda Y; Ueda A; Mihara H; Ando T; Fujinami H; Nishikawa J; Ogawa K; Minemura M; Sugiyama T
    Am J Clin Oncol; 2016 Feb; 39(1):13-7. PubMed ID: 24322336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CALGB 80403 (Alliance)/E1206: A Randomized Phase II Study of Three Chemotherapy Regimens Plus Cetuximab in Metastatic Esophageal and Gastroesophageal Junction Cancers.
    Enzinger PC; Burtness BA; Niedzwiecki D; Ye X; Douglas K; Ilson DH; Villaflor VM; Cohen SJ; Mayer RJ; Venook A; Benson AB; Goldberg RM
    J Clin Oncol; 2016 Aug; 34(23):2736-42. PubMed ID: 27382098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multicenter retrospective study of cetuximab plus platinum-based chemotherapy for recurrent or metastatic oral squamous cell carcinoma.
    Yanamoto S; Umeda M; Kioi M; Kirita T; Yamashita T; Hiratsuka H; Yokoo S; Tanzawa H; Uzawa N; Shibahara T; Ota Y; Kurita H; Okura M; Hamakawa H; Kusukawa J; Tohnai I
    Cancer Chemother Pharmacol; 2018 Mar; 81(3):549-554. PubMed ID: 29383483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I/II study of divided-dose docetaxel, cisplatin and fluorouracil for patients with recurrent or metastatic squamous cell carcinoma of the esophagus.
    Ojima T; Nakamori M; Nakamura M; Katsuda M; Hayata K; Matsumura S; Iwahashi M; Yamaue H
    Dis Esophagus; 2017 Feb; 30(2):1-7. PubMed ID: 26725778
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase 2 trial of induction nab-paclitaxel and cetuximab given with cisplatin and 5-fluorouracil followed by concurrent cisplatin and radiation for locally advanced squamous cell carcinoma of the head and neck.
    Adkins D; Ley J; Trinkaus K; Thorstad W; Lewis J; Wildes T; Siegel BA; Dehdashti F; Gay H; Mehan P; Nussenbaum B
    Cancer; 2013 Feb; 119(4):766-73. PubMed ID: 22991252
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.